SGRY - Surgery Partners Inc Stock Price, Fair Value and News

24.46USD-0.25 (-1.01%)Market Closed

Market Summary

USD24.46-0.25

Market Closed

-1.01%

SGRY Alerts

1 major insider sales recently.

SGRY Stock Price

View Fullscreen

SGRY RSI Chart

SGRY Valuation

Market Cap

3.1B

Price/Earnings (Trailing)

-260.24

Price/Sales (Trailing)

1.13

Price/Free Cashflow

15.11

SGRY Price/Sales (Trailing)

SGRY Profitability

Operating Margin

48.69%

Return on Equity

-0.6%

Return on Assets

-0.17%

Free Cashflow Yield

6.62%

SGRY Fundamentals

SGRY Revenue

Revenue (TTM)

2.7B

Rev. Growth (Yr)

Rev. Growth (Qtr)

9.09%

SGRY Earnings

Earnings (TTM)

-11.9M

Earnings Growth (Yr)

95.73%

Earnings Growth (Qtr)

79.59%

Breaking Down SGRY Revenue

Last 7 days

-6.8%

Last 30 days

-11.1%

Last 90 days

-24.1%

Trailing 12 Months

-35.3%

How does SGRY drawdown profile look like?

SGRY Financial Health

Current Ratio

1.71

Debt/Equity

1.36

Debt/Cashflow

0.11

SGRY Investor Care

Shares Dilution (1Y)

0.46%

Diluted EPS (TTM)

-0.09

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	2.6B	2.7B	2.7B	2.7B
2022	2.3B	2.4B	2.4B	2.5B
2021	1.9B	2.1B	2.2B	2.2B
2020	1.9B	1.8B	1.8B	1.9B
2019	1.8B	1.8B	1.8B	1.8B
2018	1.5B	1.7B	1.9B	1.8B
2017	1.2B	1.2B	1.1B	1.4B
2016	1.0B	1.1B	1.1B	1.1B
2015	557.0M	713.0M	876.3M	959.9M
2014	314.3M	343.9M	373.6M	403.3M
2013	0	0	0	284.6M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Surgery Partners Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 14, 2024	doherty david t	sold	-20,613	28.59	-721	chief financial officer
Mar 13, 2024	evans jason eric	sold	-143,796	29.71	-4,840	chief executive officer
Mar 12, 2024	taparo anthony	sold	-23,507	29.87	-787	chief growth officer
Mar 12, 2024	burkhalter danielle	sold	-3,301	29.74	-111	chief human resources officer
Mar 12, 2024	baldock jennifer	sold	-27,420	29.74	-922	chief admin & dev officer
Mar 12, 2024	owens bradley r.	sold	-82,989	29.82	-2,783	national group president
Mar 11, 2024	taparo anthony	sold	-19,230	29.54	-651	chief growth officer
Mar 11, 2024	burkhalter danielle	sold	-3,757	29.59	-127	chief human resources officer
Mar 11, 2024	evans jason eric	sold	-58,409	29.44	-1,984	chief executive officer
Mar 11, 2024	owens bradley r.	sold	-18,637	29.49	-632	national group president

Which funds bought or sold SGRY recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 12, 2024	AdvisorNet Financial, Inc	sold off	-100	-384	-	-%
Apr 05, 2024	CWM, LLC	added	38.84	1,000	5,000	-%
Apr 05, 2024	LOS ANGELES CAPITAL MANAGEMENT LLC	added	21.37	73,375	630,129	-%
Apr 05, 2024	GAMMA Investing LLC	unchanged	-	-15.00	537	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	reduced	-35.02	-3,841	9,438	-%
Mar 11, 2024	VANGUARD GROUP INC	added	10.4	40,765,500	237,289,000	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	62.73	28,388,500	64,797,300	0.01%
Feb 28, 2024	AMERICAN INTERNATIONAL GROUP, INC.	added	11.53	216,670	1,202,600	-%
Feb 16, 2024	WESBANCO BANK INC	sold off	-100	-750,643	-	-%
Feb 16, 2024	PRICE T ROWE ASSOCIATES INC /MD/	reduced	-28.86	-10,106,000	35,436,000	-%

Are Funds Buying or Selling SGRY?

Are funds buying SGRY calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SGRY

No. of Funds

SGRY Alerts

1 major insider sales recently.

Unveiling Surgery Partners Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	5.86%	7,417,609	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 08, 2024	wellington management group llp	6.58%	8,318,176	SC 13G/A
Dec 21, 2023	bcpe seminole holdings lp	8.5%	10,708,102	SC 13D/A
Mar 03, 2023	bcpe seminole holdings lp	10.2%	12,888,766	SC 13D/A
Feb 13, 2023	durable capital partners lp	4.6%	5,672,185	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 09, 2023	vanguard group inc	5.02%	5,870,110	SC 13G
Feb 06, 2023	wellington management group llp	5.81%	6,794,478	SC 13G
Dec 27, 2022	bcpe seminole holdings lp	10.5%	12,888,766	SC 13D/A

Recent SEC filings of Surgery Partners Inc

View All Filings

Date Filed	Form Type	Document
Apr 10, 2024	8-K	Current Report
Apr 05, 2024	4	Insider Trading
Apr 05, 2024	4	Insider Trading
Apr 05, 2024	4	Insider Trading
Apr 05, 2024	4	Insider Trading
Apr 05, 2024	4	Insider Trading
Mar 26, 2024	8-K	Current Report
Mar 26, 2024	8-K	Current Report
Mar 15, 2024	4	Insider Trading
Mar 14, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to Surgery Partners Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
UNH	441.4B	371.6B	-1.70%	-5.10%	19.72	1.19	14.64%	11.24%
CI	101.2B	195.3B	-1.86%	33.27%	18.83	0.52	8.17%	-20.79%
CVS	86.3B	357.8B	-11.58%	-9.18%	10.33	0.24	10.95%	93.52%
HCA	82.3B	65.0B	-4.91%	14.61%	15.7	1.27	7.86%	-7.11%
CNC	38.5B	154.0B	-6.56%	4.41%	14.25	0.25	6.54%	124.79%
DVA	11.2B	12.1B	-6.85%	52.87%	16.19	0.92	4.57%	23.40%
UHS	11.1B	14.3B	-9.76%	16.96%	15.45	0.78	6.59%	6.24%
MID-CAP
CHE	9.1B	2.3B	-6.80%	8.45%	33.56	4.04	6.06%	9.17%
ACHC	6.5B	2.9B	-10.10%	-6.68%	-299.27	2.21	12.20%	-107.93%
AMN	2.1B	3.8B	-10.37%	-33.80%	10.13	0.56	-27.73%	-52.50%
AMEH	2.1B	1.4B	-5.48%	-7.06%	34.14	1.49	21.19%	34.42%
SMALL-CAP
ADUS	1.6B	1.1B	-4.65%	-11.57%	25.05	1.48	11.31%	35.83%
BKD	1.2B	3.0B	5.90%	51.29%	-6.47	0.41	6.74%	20.73%
BEAT	56.9M	-	-6.90%	0.47%	-3.88	-	-	-12.94%
AMS	18.7M	21.3M	15.18%	4.04%	35.15	0.88	8.00%	-62.25%

Surgery Partners Inc News

Latest updates

Surgery Partners Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	9.1%	735	674	668	666	707	621	615	596	610	559	543	512	548	496	375	441	517	452	445	417	491
Cost Of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	388	353	340	326	360
Operating Expenses	7.2%	634	592	570	620	613	547	539	496	495	496	484	448	452	478	330	418	445	393	390	367	543
S&GA Expenses	-43.2%	21.00	37.00	31.00	32.00	29.00	18.00	26.00	30.00	27.00	26.00	25.00	27.00	24.00	25.00	25.00	23.00	24.00	20.00	23.00	22.00	24.00
Income Taxes	93.5%	6.00	3.00	-7.80	-1.60	10.00	8.00	4.00	1.00	12.00	1.00	-2.70	0.00	-5.60	1.00	-0.60	-15.20	4.00	2.00	1.00	2.00	16.00
Net Income	79.6%	-1.00	-4.90	19.00	-24.90	-23.40	-25.00	-18.40	12.00	-0.10	-22.90	-26.90	-21.00	6.00	-61.60	-32.50	-27.50	-19.20	-15.70	-19.80	-20.10	-147
Net Income Margin	65.7%	0.00*	-0.01*	-0.02*	-0.04*	-0.02*	-0.01*	-0.01*	-0.02*	-0.03*	-0.03*	-0.05*	-0.06*	-	-	-	-	-	-	-	-	-
Free Cashflow	-50.1%	43.00	86.00	26.00	50.00	-15.50	12.00	20.00	62.00	6.00	-0.60	-11.20	36.00	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	1.4%	6,877	6,780	6,621	6,643	6,682	6,537	6,292	6,290	6,118	5,632	5,621	5,639	5,413	5,313	5,245	5,091	5,019	4,918	4,891	4,881	4,676
Current Assets	2.1%	895	876	810	869	921	738	788	937	946	842	953	1,018	802	893	747	615	526	518	529	535	588
Cash Equivalents	-17.0%	196	236	177	246	283	155	227	379	390	330	465	542	318	450	327	195	93.00	112	118	143	185
Inventory	8.4%	75.00	69.00	70.00	72.00	71.00	69.00	64.00	63.00	61.00	59.00	57.00	56.00	56.00	51.00	49.00	49.00	46.00	44.00	44.00	44.00	43.00
Goodwill	-	4,326	-	-	-	4,137	-	-	-	3,912	-	-	-	3,468	-	-	-	3,402	3,406	3,402	3,393	3,383
Current Liabilities	4.3%	523	501	459	475	493	624	522	542	537	541	532	575	557	591	571	412	398	382	369	360	349
Long Term Debt	2.3%	2,702	2,640	2,505	2,531	2,559	3,103	3,019	3,025	2,878	2,792	2,786	2,790	2,792	2,761	2,623	2,627	2,525	2,403	2,397	2,385	2,271
Shareholder's Equity	-0.9%	1,987	2,005	2,983	2,943	1,998	2,105	2,041	2,013	1,970	1,552	1,527	1,105	882	801	896	923	983	1,007	1,045	1,084	1,099
Retained Earnings	-0.2%	-569	-568	-563	-582	-557	-533	-508	-490	-502	-502	-479	-452	-431	-	-	-343	-315	-284	-268	-249	-247
Additional Paid-In Capital	0.1%	2,498	2,495	2,501	2,478	2,478	1,623	1,619	1,625	1,622	1,306	1,298	843	608	-	-	655	663	670	678	674	674
Accumulated Depreciation	-	-	-	-	-	-	-	-	-	-	-	231	216	189	171	152	130	111	98.00	75.00	60.00	56.00
Shares Outstanding	0.1%	127	126	126	126	126	89.00	88.00	88.00	72.00	81.00	69.00	55.00	-	-	-	-	-	-	-	-	-
Minority Interest	6.7%	1,047	982	965	981	943	933	885	852	881	796	762	769	767	700	692	687	687	678	686	693	694
Float	-	-	-	4,700	-	-	-	1,100	-	-	-	2,100	-	-	-	256	-	-	-	175	-	-

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-40.2%	63.00	105	52.00	75.00	7.00	30.00	42.00	80.00	20.00	15.00	2.00	50.00	9.00	27.00	182	29.00	25.00	57.00	27.00	21.00	46.00
Share Based Compensation	2.3%	5.00	4.00	5.00	4.00	5.00	5.00	4.00	4.00	4.00	4.00	4.00	5.00	3.00	3.00	3.00	4.00	3.00	3.00	3.00	2.00	3.00
Cashflow From Investing	-127.0%	-58.10	-25.60	-71.20	-70.70	-72.20	-54.30	-134	-47.10	-190	-101	-26.40	-14.30	-95.20	29.00	-14.80	-7.70	-23.40	-18.90	-24.50	-18.40	-62.30
Cashflow From Financing	-118.6%	-44.60	-20.40	-49.00	-41.20	193	-48.00	-59.30	-43.70	230	-48.30	-53.00	188	-45.80	68.00	-35.40	80.00	-20.60	-44.10	-27.30	-43.90	122
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

SGRY Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Millions

12 Months Ended

Dec. 31, 2023

Dec. 31, 2022

Dec. 31, 2021

Income Statement [Abstract]

Revenues

$ 2,743.3

$ 2,539.3

$ 2,225.1

Operating expenses:

Salaries and benefits

793.8

746.4

644.3

Supplies

745.0

709.7

636.4

Professional and medical fees

296.8

269.2

230.0

Lease expense

84.9

82.4

90.6

Other operating expenses

175.3

156.7

132.4

Cost of revenues

2,095.8

1,964.4

1,733.7

General and administrative expenses

120.9

102.2

104.0

Depreciation and amortization

118.1

114.8

98.8

Transaction and integration costs

61.7

47.5

39.8

Grant funds

(1.1)

(2.4)

(37.9)

Net loss on disposals, consolidations and deconsolidations

14.4

11.1

2.2

Equity in earnings of unconsolidated affiliates

(14.2)

(12.5)

(11.3)

Litigation settlements

10.6

(29.3)

0.0

Loss on debt extinguishment

15.5

14.9

9.1

Other income, net

(6.4)

(16.6)

(15.5)

Total operating expenses

2,415.3

2,194.1

1,922.9

Operating income

328.0

345.2

302.2

Interest expense, net

(193.0)

(234.9)

(221.0)

Income before income taxes

135.0

110.3

81.2

Income tax benefit (expense)

0.3

(23.3)

(10.5)

Net income

135.3

87.0

70.7

Less: Net income attributable to non-controlling interests

(147.2)

(141.6)

Net loss attributable to Surgery Partners, Inc.

(11.9)

(54.6)

(70.9)

Less: Amounts attributable to participating securities

0.0

(10.3)

Net loss attributable to common stockholders

(11.9)

(54.6)

(81.2)

Net loss attributable to common stockholders (diluted)

$ (11.9)

$ (54.6)

$ (81.2)

Net loss per share attributable to common stockholders:

Basic (in USD per share)

$ (0.09)

$ (0.59)

$ (1.12)

Diluted (in USD per share)

^[1]

$ (0.09)

$ (0.59)

$ (1.12)

Weighted average common shares outstanding:

Basic (shares)

125,613

91,952

72,427

Diluted (shares)

^[1]

125,613

91,952

72,427

[1]	The impact of potentially dilutive securities for all periods were not considered because the effect would be anti-dilutive.

SGRY Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 195.9	$ 282.9
Accounts receivable	496.4	456.3
Inventories	75.2	71.4
Prepaid expenses	31.0	31.4
Other current assets	96.5	79.0
Total current assets	895.0	921.0
Property and equipment, net	968.7	876.6
Intangible assets, net	54.8	42.3
Goodwill	4,326.0	4,137.1
Investments in and advances to affiliates	184.1	190.3
Right-of-use operating lease assets	255.3	279.1
Long-term deferred tax assets	89.5	91.5
Other long-term assets	103.3	144.2
Total assets	6,876.7	6,682.1
Current liabilities:
Accounts payable	171.8	151.6
Accrued payroll and benefits	73.8	68.9
Other current liabilities	204.1	210.1
Current maturities of long-term debt	73.3	62.8
Total current liabilities	523.0	493.4
Long-term debt, less current maturities	2,701.8	2,559.0
Right-of-use operating lease liabilities	248.9	271.4
Other long-term liabilities	41.1	75.4
Non-controlling interests—redeemable	327.4	342.0
Stockholders' equity:
Preferred stock, $0.01 par value; shares authorized - 20,310,000; shares issued or outstanding - none	0.0	0.0
Common stock, $0.01 par value; shares authorized - 300,000,000; shares issued and outstanding - 126,593,727 and 125,960,834, respectively	1.3	1.3
Additional paid-in capital	2,497.6	2,478.0
Accumulated other comprehensive income	57.5	76.2
Retained deficit	(569.2)	(557.3)
Total Surgery Partners, Inc. stockholders' equity	1,987.2	1,998.2
Non-controlling interests—non-redeemable	1,047.3	942.7
Total stockholders' equity	3,034.5	2,940.9
Total liabilities and stockholders' equity	$ 6,876.7	$ 6,682.1

About Surgery Partners Inc

Surgery Partners, Inc., through its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company operates through two segments, Surgical Facility Services and Ancillary Services. Its surgical facilities comprise ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery. The company's surgical hospitals also provide ancillary services, such as diagnostic imaging, laboratory, obstetrics, oncology, pharmacy, physical therapy, and wound care; and ancillary services, including multi-specialty physician practices, urgent care facilities, and anesthesia services. The company was founded in 2004 and is headquartered in Brentwood, Tennessee.

CEO	Mr. J. Eric Evans
WEBSITE	surgerypartners.com
INDUSTRY	Healthcare Plans
EMPLOYEES	9100

Surgery Partners Inc Frequently Asked Questions

What is the ticker symbol for Surgery Partners Inc? What does SGRY stand for in stocks?

SGRY is the stock ticker symbol of Surgery Partners Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Surgery Partners Inc (SGRY)?

As of Wed Apr 17 2024, market cap of Surgery Partners Inc is 3.1 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SGRY stock?

You can check SGRY's fair value in chart for subscribers.

What is the fair value of SGRY stock?

You can check SGRY's fair value in chart for subscribers. The fair value of Surgery Partners Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Surgery Partners Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SGRY so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Surgery Partners Inc a good stock to buy?

The fair value guage provides a quick view whether SGRY is over valued or under valued. Whether Surgery Partners Inc is cheap or expensive depends on the assumptions which impact Surgery Partners Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SGRY.

What is Surgery Partners Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 17 2024, SGRY's PE ratio (Price to Earnings) is -260.24 and Price to Sales (PS) ratio is 1.13. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SGRY PE ratio will change depending on the future growth rate expectations of investors.